"AlloVir and Kalaris enter merger to advance retinal disease therapies" was originally created and published by ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

AlloVir (ALVR) announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock ...

Shares of AlloVir tumbled in premarket trading Friday after the immunotherapy company said it has agreed to an all-stock reverse merger with clinical-stage biopharmaceutical company Kalaris ...

and PALO ALTO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR) today announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics ...

AlloVir (ALVR) stock falls as comany agrees to an all-stock merger transaction with Kalaris Therapeutics. Read more here.

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders ...